<DOC>
	<DOCNO>NCT02101086</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety autologous cord blood transfusion very-low-birth-weight premature infant , evaluate developmental outcome infant receive autologous transfusion .</brief_summary>
	<brief_title>Autologous Cord Blood Transfusion Preterm Infants</brief_title>
	<detailed_description>Blood transfusion many risk include transfusion reaction infection . Cord blood accept alternative method red cell transfusion low-birth weight ( LBW ) premature newborn . However , experience scientific evidence concern in-vivo efficacy safety red blood cell ( RBC ) concentrate derive cord blood LBW premature newborn still insufficient . A total 50 umbilical cord blood ( UCB ) collect infant born 32 week ' gestational age process autologous RBC product . Infants require blood transfusion randomly assign autologous allogeneic product . Two randomize group compare 14th , 28th , 35th day &gt; 35th day respect hemoglobin level , transfusion number , transfusion phlebotomy volume , hemoglobin , reticulocyte count erythropoietin level postconceptional 36th 40th week ' gestation , hemoglobin level postnatal 6-months age . All transfuse infant developmentally assessed end postnatal first year .</detailed_description>
	<criteria>Preterm infant bear â‰¤ 32 week gestational age Parental consent rhesus incompatibility hydrops fetalis maternal viral bacterial infection include suspected chorioamnionitis parental refuse</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>umbilical cord blood</keyword>
	<keyword>premature</keyword>
	<keyword>autologous transfusion</keyword>
	<keyword>allogeneic transfusion</keyword>
</DOC>